Generative AI in Biopharma: Data-Driven Impact on R&D Productivity
The biopharmaceutical industry faces a stark paradox: while R&D expenditures have surged beyond $200 billion annually across major players like Pfizer, Roche, and Novartis, the number of approved new molecular entities per billion dollars invested has declined approximately 80% since 1950—a phenomenon known as Eroom's Law. Phase II and Phase III clinical trial failure rates consistently exceed 65%, with oncology programs reaching 75% failure at pivotal stages. Regulatory submission cycles stretch 18-24 months from database lock to approval, while patent cliff pressures intensify as biosimilars erode blockbuster revenues. Against this backdrop, Generative AI in Biopharma has emerged not as speculative technology but as a quantifiable lever for reversing productivity decline across discovery biology, clinical development operations, and regulatory affairs. The economic case for Generative AI in Biopharma rests on measurable gains in three critical dimensions: cycle time compress...